Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Queensland Health
Baxter
Covington
QuintilesIMS
Moodys

Generated: August 24, 2019

DrugPatentWatch Database Preview

Patent: 9,132,199

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,132,199
Title:Reverse thermal gels and uses therefor
Abstract: Biodegradable triblock copolymer compositions are provided which are useful in tissue engineering and drug delivery. The copolymers are reverse thermal gels in that when heated from a lower temperature to a higher temperature, they gel. These gels are useful in drug delivery when complexed with an active agent. For example the compositions can be used for intraocular injection of active agents, such as anti-angiogenic agents for treatment of a maculopathy or retinitis.
Inventor(s): Friberg; Thomas R. (Pittsburgh, PA), Park; Daewon (Pittsburgh, PA), Wang; Yadong (Allison Park, PA)
Assignee: University of Pittsburgh--Of the Commonwealth System of Higher Education (Pittsburgh, PA)
Application Number:13/581,518
Patent Claims:see list of patent claims

Details for Patent 9,132,199

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech LUCENTIS ranibizumab INJECTABLE; INJECTION 125156 001 2006-06-30 ➤ Sign Up University of Pittsburgh--Of the Commonwealth System of Higher Education (Pittsburgh, PA) 2030-03-05 RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26 ➤ Sign Up University of Pittsburgh--Of the Commonwealth System of Higher Education (Pittsburgh, PA) 2030-03-05 RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26 ➤ Sign Up University of Pittsburgh--Of the Commonwealth System of Higher Education (Pittsburgh, PA) 2030-03-05 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Fuji
Federal Trade Commission
Mallinckrodt
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.